- Joined
- Dec 22, 2007
- Messages
- 8,190
Any CBD sponsors here on PM?
Right. So based on that data, the product developed by you has a roughly 9x higher bioavailability than the liposomal CBD. The latter has a bioavailability of somewhere between 30 and 90% (see https://www.ncbi.nlm.nih.gov/pubmed/27648135/ and https://www.ncbi.nlm.nih.gov/pubmed/28736128). So if the data you posted were correct, then your product would have a bioavailibility of at least 180% Absolutely ridiculous claims, if you're gonna make up data to sell your products then at least make it somewhat believableCBD Bioavailability: Best Bioavailable CBD Delivery Methods
Cannabis pioneers are searching for best ways to enhance CBD & include nano-emulsions, liposomal colloids, cannabimimetic compounds, & endocannabinoid enhancers.www.growthcellglobal.com
Plasma levels of CBD were increased when CBD was administered with food or in a fed state, or when a meal is consumed post-administration. Oral capsules with piperine pro-nanolipospheres also increased AUC and Cmax. This is also demonstrated in animal studies; co-administration of lipids with oral CBD increased systemic availability by almost 3-fold in rats (Zgair et al., 2016) and a pro-nanoliposphere formulation increased oral bioavailability by about 6-fold (Cherniakov et al., 2017b). As CBD is a highly lipophilic molecule, it is logical that CBD may dissolve in the fat content of food, increasing its solubility, and absorption and therefore bioavailability as demonstrated by numerous pharmacological drugs (Winter et al., 2013). Thus, it may be advisable to administer CBD orally in a fed state to allow for optimal absorption.
There has been an escalating interest in the medicinal use of Cannabis sativa in recent years. Cannabis is often administered orally with fat-containing foods, or in lipid-based pharmaceutical preparations. However, the impact of lipids on the exposure of patients to cannabis components has not been explored. Therefore, the aim of this study is to elucidate the effect of oral co-administration of lipids on the exposure to two main active cannabinoids, Δ(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD). In this study, oral co-administration of lipids enhanced the systemic exposure of rats to THC and CBD by 2.5-fold and 3-fold, respectively, compared to lipid-free formulations. In vitro lipolysis was conducted to explore the effect of lipids on the intestinal solubilisation of cannabinoids. More than 30% of THC and CBD were distributed into micellar fraction following lipolysis, suggesting that at least one-third of the administered dose will be available for absorption following co-administration with lipids. Both cannabinoids showed very high affinity for artificial CM-like particles, as well as for rat and human CM, suggesting high potential for intestinal lymphatic transport. Moreover, comparable affinity of cannabinoids for rat and human CM suggests that similar increased exposure effects may be expected in humans. In conclusion, co-administration of dietary lipids or pharmaceutical lipid excipients has the potential to substantially increase the exposure to orally administered cannabis and cannabis-based medicines. The increase in patient exposure to cannabinoids is of high clinical importance as it could affect the therapeutic effect, but also toxicity, of orally administered cannabis or cannabis-based medicines.
The lipophilic phytocannabinoids cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) show therapeutic efficacy in various medical conditions. Both molecules are poorly water soluble and subjected to extensive first pass metabolism in the gastrointestinal tract, leading to a limited oral bioavailability of approximately 9%. We have developed an advanced lipid based Self-Emulsifying Drug Delivery System termed Advanced Pro-NanoLiposphere (PNL) pre-concentrate. The PNL is composed of lipid and emulsifying excipients of GRAS status and are known to increase solubility and reduce Phase I metabolism of lipophilic active compounds. Advanced PNLs are PNLs with an incorporated natural absorption enhancers. These molecules are natural alkaloids and phenolic compounds which were reported to inhibit certain phase I and phase II metabolism processes. Here we use piperine, curcumin and resveratrol to formulate the Advanced-PNL formulations. Consequently, we have explored the utility of these Advanced-PNLs on CBD and THC oral bioavailability. Oral administration of CBD-piperine-PNL resulted in 6-fold increase in AUC compared to CBD solution, proving to be the most effective of the screened formulations. The same trend was found in pharmacokinetic experiments of THC-piperine-PNL which resulted in a 9.3-fold increase in AUC as compared to THC solution. Our Piperine-PNL can be used as a platform for synchronized delivery of piperine and CBD or THC to the enterocyte site. This co-localization provides an increase in CBD and THC bioavailability by its effect at the pre-enterocyte and the enterocyte levels of the absorption process. The extra augmentation in the absorption of CBD and THC by incorporating piperine into PNL is attributed to the inhibition of Phase I and phase II metabolism by piperine in addition to the Phase I metabolism and P-gp inhibition by PNL. These novel results pave the way to utilize piperine-PNL delivery system for other poorly soluble, highly metabolized compounds that currently cannot be administered orally.
No, see attachment.So in lay terms: consume a high quality THC/CBD product with or right after a meal high in fats with a quality Curcumin & Bioperine supplement for optimal absorption?
YesRight. So based on that data, the product developed by you has a roughly 9x higher bioavailability than the liposomal CBD. The latter has a bioavailability of somewhere between 30 and 90% (see https://www.ncbi.nlm.nih.gov/pubmed/27648135/ and https://www.ncbi.nlm.nih.gov/pubmed/28736128). So if the data you posted were correct, then your product would have a bioavailibility of at least 180% Absolutely ridiculous claims, if you're gonna make up data to sell your products then at least make it somewhat believable
Of course, the addition of peptides and BCAA (!?) to CBD make absolutely no sense and there is no mechanism through which these would increase CBD's bioavailability and thereby blood concentration. I'm glad your earlier post where you advertised your snake oil was removed.
For anyone who wants to actually understand how to maximize the bioavailability of their CBD, the following scientific articles may be more suited than some BS marketing material.
A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans
Background: Cannabidiol is being pursued as a therapeutic treatment for multiple conditions, usually by oral delivery. Animal studies suggest oral bioavailability is low, but literature in humans is not sufficient. The aim of this review was to collate ...www.ncbi.nlm.nih.gov
Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines - PubMed
There has been an escalating interest in the medicinal use of Cannabis sativa in recent years. Cannabis is often administered orally with fat-containing foods, or in lipid-based pharmaceutical preparations. However, the impact of lipids on the exposure of patients to cannabis components has not...www.ncbi.nlm.nih.gov
The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model - PubMed
The lipophilic phytocannabinoids cannabidiol (CBD) and Δ<sup>9</sup>-tetrahydrocannabinol (THC) show therapeutic efficacy in various medical conditions. Both molecules are poorly water soluble and subjected to extensive first pass metabolism in the gastrointestinal tract, leading to a limited...www.ncbi.nlm.nih.gov
The BCAA is just a filer, to fill up the capsules.Right. So based on that data, the product developed by you has a roughly 9x higher bioavailability than the liposomal CBD. The latter has a bioavailability of somewhere between 30 and 90% (see https://www.ncbi.nlm.nih.gov/pubmed/27648135/ and https://www.ncbi.nlm.nih.gov/pubmed/28736128). So if the data you posted were correct, then your product would have a bioavailibility of at least 180% Absolutely ridiculous claims, if you're gonna make up data to sell your products then at least make it somewhat believable
Of course, the addition of peptides and BCAA (!?) to CBD make absolutely no sense and there is no mechanism through which these would increase CBD's bioavailability and thereby blood concentration. I'm glad your earlier post where you advertised your snake oil was removed.
For anyone who wants to actually understand how to maximize the bioavailability of their CBD, the following scientific articles may be more suited than some BS marketing material.
A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans
Background: Cannabidiol is being pursued as a therapeutic treatment for multiple conditions, usually by oral delivery. Animal studies suggest oral bioavailability is low, but literature in humans is not sufficient. The aim of this review was to collate ...www.ncbi.nlm.nih.gov
Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines - PubMed
There has been an escalating interest in the medicinal use of Cannabis sativa in recent years. Cannabis is often administered orally with fat-containing foods, or in lipid-based pharmaceutical preparations. However, the impact of lipids on the exposure of patients to cannabis components has not...www.ncbi.nlm.nih.gov
The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model - PubMed
The lipophilic phytocannabinoids cannabidiol (CBD) and Δ<sup>9</sup>-tetrahydrocannabinol (THC) show therapeutic efficacy in various medical conditions. Both molecules are poorly water soluble and subjected to extensive first pass metabolism in the gastrointestinal tract, leading to a limited...www.ncbi.nlm.nih.gov
The group receiving the oligopeptide mixture experienced significantly higher average levels of CBD. Peak CBD was achieved at the 9-hour mark, with the non-oligopeptide complex group reaching 89.74 ng/ml and the oligopeptide group averaging 154.38ng/ml.Right. So based on that data, the product developed by you has a roughly 9x higher bioavailability than the liposomal CBD. The latter has a bioavailability of somewhere between 30 and 90% (see https://www.ncbi.nlm.nih.gov/pubmed/27648135/ and https://www.ncbi.nlm.nih.gov/pubmed/28736128). So if the data you posted were correct, then your product would have a bioavailibility of at least 180% Absolutely ridiculous claims, if you're gonna make up data to sell your products then at least make it somewhat believable
Of course, the addition of peptides and BCAA (!?) to CBD make absolutely no sense and there is no mechanism through which these would increase CBD's bioavailability and thereby blood concentration. I'm glad your earlier post where you advertised your snake oil was removed.
For anyone who wants to actually understand how to maximize the bioavailability of their CBD, the following scientific articles may be more suited than some BS marketing material.
A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans
Background: Cannabidiol is being pursued as a therapeutic treatment for multiple conditions, usually by oral delivery. Animal studies suggest oral bioavailability is low, but literature in humans is not sufficient. The aim of this review was to collate ...www.ncbi.nlm.nih.gov
Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines - PubMed
There has been an escalating interest in the medicinal use of Cannabis sativa in recent years. Cannabis is often administered orally with fat-containing foods, or in lipid-based pharmaceutical preparations. However, the impact of lipids on the exposure of patients to cannabis components has not...www.ncbi.nlm.nih.gov
The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model - PubMed
The lipophilic phytocannabinoids cannabidiol (CBD) and Δ<sup>9</sup>-tetrahydrocannabinol (THC) show therapeutic efficacy in various medical conditions. Both molecules are poorly water soluble and subjected to extensive first pass metabolism in the gastrointestinal tract, leading to a limited...www.ncbi.nlm.nih.gov
Don`t embarrass yourself.Right. So based on that data, the product developed by you has a roughly 9x higher bioavailability than the liposomal CBD. The latter has a bioavailability of somewhere between 30 and 90% (see https://www.ncbi.nlm.nih.gov/pubmed/27648135/ and https://www.ncbi.nlm.nih.gov/pubmed/28736128). So if the data you posted were correct, then your product would have a bioavailibility of at least 180% Absolutely ridiculous claims, if you're gonna make up data to sell your products then at least make it somewhat believable
Of course, the addition of peptides and BCAA (!?) to CBD make absolutely no sense and there is no mechanism through which these would increase CBD's bioavailability and thereby blood concentration. I'm glad your earlier post where you advertised your snake oil was removed.
For anyone who wants to actually understand how to maximize the bioavailability of their CBD, the following scientific articles may be more suited than some BS marketing material.
A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans
Background: Cannabidiol is being pursued as a therapeutic treatment for multiple conditions, usually by oral delivery. Animal studies suggest oral bioavailability is low, but literature in humans is not sufficient. The aim of this review was to collate ...www.ncbi.nlm.nih.gov
Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines - PubMed
There has been an escalating interest in the medicinal use of Cannabis sativa in recent years. Cannabis is often administered orally with fat-containing foods, or in lipid-based pharmaceutical preparations. However, the impact of lipids on the exposure of patients to cannabis components has not...www.ncbi.nlm.nih.gov
The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model - PubMed
The lipophilic phytocannabinoids cannabidiol (CBD) and Δ<sup>9</sup>-tetrahydrocannabinol (THC) show therapeutic efficacy in various medical conditions. Both molecules are poorly water soluble and subjected to extensive first pass metabolism in the gastrointestinal tract, leading to a limited...www.ncbi.nlm.nih.gov
wait, am I missing something? Why would anybody want to maximize the bioavailability of CBD? Its cheap as dirt, why not just up your dose of oil? Its not like the oil itself is bad for you...full spectrum high strength CBD oil actually is great for you in other aspects also.
The group receiving the oligopeptide mixture experienced significantly higher average levels of CBD. Peak CBD was achieved at the 9-hour mark, with the non-oligopeptide complex group reaching 89.74 ng/ml and the oligopeptide group averaging 154.38ng/ml.
These results were determined at a US Navy Laboratory in China Lake, California. The elevated levels of CBD are significantly higher than other conventional CBD enhancement technologies.